AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ALLERGY THERAPEUTICS PLC

Report Publication Announcement Feb 23, 2016

7477_rns_2016-02-23_a1b65e65-eb52-4701-b5c0-63a9654fd6aa.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7981P

Allergy Therapeutics PLC

23 February 2016

23 February 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Notice of Interim Results

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will issue its interim results for the six month period ended 31 December 2015 on Tuesday 8th March 2016.

A meeting for analysts will be held at 9:30am at the offices of Panmure Gordon at 1 New Change, London, EC4M 9AF. Manuel Llobet, Chief Executive Officer, and Ian Postlethwaite, Chief Financial Officer, will provide an update on the Company with a Q&A session which will be accessible remotely via a live conference call. The details of the call will be provided in the statement on Tuesday 8th March.

- ENDS -

For further information please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

[email protected]

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information please see www.allergytherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORDLLFLQLFXBBD

Talk to a Data Expert

Have a question? We'll get back to you promptly.